News
RHHVF
415.00
+1.22%
5.00
Roche To Acquire PathAI: Smart Dealmaking By A Smart Pharma
Seeking Alpha · 1d ago
Davis to become acting director of CDER after Hoeg exit, Bloomberg says
TipRanks · 1d ago
FDA approves Genentech’s Tecentriq for adjuvant muscle-invasive bladder cancer
TipRanks · 1d ago
Signatera CDx approved by FDA as companion diagnostic in MIBC
TipRanks · 1d ago
FDA approves Genentech Tecentriq as adjuvant ctDNA-guided therapy for muscle-invasive bladder cancer
PUBT · 1d ago
FDA approves Roche’s Tecentriq for ctDNA-guided adjuvant muscle-invasive bladder cancer treatment
PUBT · 1d ago
FDA: APPROVES NATERA'S SIGNATERA CDX AS COMPANION DIAGNOSTIC FOR TECENTRIQ BLADDER CANCER TREATMENT FOR SOME PATIENTS - WEBSITE
Reuters · 1d ago
FDA APPROVES ATEZOLIZUMAB FOR ADJUVANT TREATMENT OF MUSCLE INVASIVE BLADDER CANCER IN PATIENTS WITH MOLECULAR RESIDUAL DISEASE
Reuters · 1d ago
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting
Seeking Alpha · 2d ago
Trump Trade: Nvidia CEO joins China trip, Diamantas tapped as acting FDA chief
TipRanks · 3d ago
UPDATE 2-US FDA approves BeOne's drug for a type of blood cancer
Reuters · 3d ago
UBS Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
TipRanks · 4d ago
FDA Commissioner Marty Makary resigns
TipRanks · 4d ago
Trump confirms Kyle Diamantas to be acting head of FDA
TipRanks · 4d ago
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
TipRanks · 4d ago
Roche receives CE Mark for Elecsys pTau217
TipRanks · 4d ago
Roche And Lilly's Elecsys pTau217 Wins CE Mark As First Single-Assay Blood Test Offering Spinal Fluid-Comparable Accuracy To Rule In And Rule Out Alzheimer's Amyloid Pathology
Benzinga · 5d ago
Roche wins CE mark for Elecsys pTau217 Alzheimer’s blood test
PUBT · 5d ago
ROCHE - RECEIVES CE MARK FOR NEW BLOOD TEST TO DETECT ALZHEIMER'S PATHOLOGY
Reuters · 5d ago
Roche gets second European approval for Alzheimer's test
Reuters · 5d ago
More
Webull provides a variety of real-time RHHVF stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHVF
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.